drugset / Trial / NCT06168734
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Phase 3
Withdrawn
Venatorx Pharmaceuticals, Inc.
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 3, randomized, multicenter, double-blind, non-inferiority study to evaluate the efficacy and safety of cefepime-taniborbactam compared to meropenem in patients ≥ 18 years of age with ventilated HABP or VABP.
Timeline
- Start
- 2025-06
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cefepime | Small molecule | 2 g | Intravenous |
| Comparator | Meropenem | Small molecule | 2 g | Intravenous |
| Subject | taniborbactam | Other / unclassified | 0.5 g | Intravenous |